Log in
NASDAQ:REGN

Regeneron Pharmaceuticals Stock Forecast, Price & News

$555.24
-9.76 (-1.73 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$544.96
Now: $555.24
$567.83
50-Day Range
$544.75
MA: $600.64
$648.43
52-Week Range
$271.37
Now: $555.24
$664.64
Volume1.98 million shs
Average Volume1.15 million shs
Market Capitalization$59.07 billion
P/E Ratio21.50
Dividend YieldN/A
Beta0.5
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Read More
Regeneron Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.86 billion
Cash Flow$24.69 per share
Book Value$100.56 per share

Profitability

Net Income$2.12 billion

Miscellaneous

Employees8,100
Market Cap$59.07 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$555.24
-9.76 (-1.73 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

How has Regeneron Pharmaceuticals' stock price been impacted by Coronavirus?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, REGN shares have increased by 19.5% and is now trading at $555.24.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Regeneron Pharmaceuticals?

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Regeneron Pharmaceuticals
.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Regeneron Pharmaceuticals
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced its quarterly earnings data on Wednesday, August, 5th. The biopharmaceutical company reported $7.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $1.57. The biopharmaceutical company had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.74 billion. Regeneron Pharmaceuticals had a net margin of 37.30% and a return on equity of 26.71%. Regeneron Pharmaceuticals's revenue was up 23.7% compared to the same quarter last year. During the same period last year, the company earned $6.02 EPS.
View Regeneron Pharmaceuticals' earnings history
.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals declared that its board has initiated a stock repurchase plan on Tuesday, November 5th 2019, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase up to 2.9% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's leadership believes its shares are undervalued.

What price target have analysts set for REGN?

27 Wall Street analysts have issued 12-month target prices for Regeneron Pharmaceuticals' shares. Their forecasts range from $325.00 to $800.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $592.78 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals
.

Are investors shorting Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals saw a decrease in short interest in August. As of August 14th, there was short interest totaling 1,600,000 shares, a decrease of 15.3% from the July 30th total of 1,890,000 shares. Based on an average daily trading volume, of 1,180,000 shares, the short-interest ratio is presently 1.4 days. Approximately 1.6% of the company's stock are sold short.
View Regeneron Pharmaceuticals' Short Interest
.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Netflix (NFLX), Gilead Sciences (GILD), Alibaba Group (BABA), Tesla (TSLA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Intel (INTC).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:
  • Dr. Schleifer Leonard S., Co-Founder, Pres, CEO & Exec. Director (Age 66)
  • Dr. George D. Yancopoulos, Founding Scientist, Pres, Chief Scientific Officer & Director (Age 59)
  • Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 55)
  • Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 46)
  • Ms. Marion E. McCourt, Sr. VP & Head of Commercial (Age 59)

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (11.71%), BlackRock Inc. (8.90%), Vanguard Group Inc. (7.13%), Nuveen Asset Management LLC (1.60%), California Public Employees Retirement System (0.76%) and Bank of New York Mellon Corp (0.70%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals
.

Which major investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Candriam Luxembourg S.C.A., Perceptive Advisors LLC, LSV Asset Management, Toronto Dominion Bank, Bank of Nova Scotia, Advisor Group Holdings Inc., and NN Investment Partners Holdings N.V.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals
.

Which major investors are buying Regeneron Pharmaceuticals stock?

REGN stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Vanguard Group Inc., California Public Employees Retirement System, Nuveen Asset Management LLC, APG Asset Management N.V., Swiss National Bank, and Bank of New York Mellon Corp.
View insider buying and selling activity for Regeneron Pharmaceuticals
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $555.24.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $59.07 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.